Latest news with #TherapeuticPlasmaExchange
Business Wire
3 days ago
- Health
- Business Wire
Next Health Announces Calabasas Expansion With Grand Opening August 15, 2025
WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Next Health, the world's most advanced brand of proactive healthcare centers, is expanding its Los Angeles footprint with a new flagship location in Calabasas. Doors are already open, with an official Grand Opening celebration set for Friday, August 15, 2025. This expansion supports Next Health's mission to bring health optimization and longevity to the most strategic wellness-forward markets in the U.S., empowering individuals to take a proactive approach to their health. Next Health, the world's most advanced brand of proactive healthcare centers, is expanding its Los Angeles footprint with a new flagship location in Calabasas. The Grand Opening will feature a ribbon-cutting ceremony and exclusive wellness panel moderated by Next Health Founder and CEO Dr. Darshan Shah, who will lead a discussion on the future of longevity. He will be joined by wellness entrepreneur, fitness icon, and long-time Next Health supporter Brooke Burke, who will share insights into her personal health journey and the lifestyle practices that fuel her approach to longevity and vitality. The Calabasas location is led by powerhouse franchise partners Barry and Lori Turbow, along with Donnie and Megan Wilson —experienced entrepreneurs whose careers span success in sports marketing, business development, and healthcare. For Lori, a trained occupational therapist, the venture is deeply personal, shaped by her own experience navigating chronic illness and a lifelong passion for helping others reclaim their health. 'We're proud to bring Next Health to Calabasas—a community that embodies innovation, vitality, and a deep commitment to wellness,' said Barry and Lori Turbow. 'After years of working in healthcare and overcoming personal challenges, we knew we wanted to create a space where people can take charge of their longevity, access breakthrough medical technologies, and experience proactive health in a whole new way.' The center offers a comprehensive suite of services, including IV Therapy, hormone optimization, peptide therapy, hyperbaric oxygen chamber, weight optimization programs, cryotherapy, ozone therapy (including EBOO: Extracorporeal Blood Oxygenation and Ozonation), Therapeutic Plasma Exchange (TPE), and Next Health's most advanced longevity protocols like Executive Physicals, Biological Age Testing, and extensive functional medicine testing. Calabasas was chosen for its concentration of health-conscious residents, influential wellness culture, and demand for proactive medical solutions in a luxury setting. The new location reflects the collaborative vision of Dr. Darshan Shah, CEO and Founder of Next Health, and Kevin Peake, President, who continue to guide the brand's rapid national expansion through carefully selected franchise partners. 'Next Health Calabasas will serve as a beacon of health optimization in Southern California,' said Shah and Peake in a joint statement. 'We are thrilled to partner with Barry and Lori Turbow and Donnie and Megan Wilson to introduce cutting-edge longevity services to this remarkable community. Our goal is to empower individuals to take control of their health and extend the human healthspan through personalized, data-driven care.' Next Health Calabasas is located in the El Camino Shopping Center, offering a state-of-the-art, hospitality-grade facility designed to make advanced wellness accessible, empowering, and luxurious. Guests are invited to experience the future of health firsthand, with personalized consultations, immersive programming, and exclusive opening-week specials to mark the occasion. Location: 23383 Mulholland Dr, Woodland Hills, CA 91364 About Next Health Next Health is a pioneer in personalized health optimization and longevity. Founded in 2016 by renowned surgeon Dr. Darshan Shah and entrepreneur Kevin Peake, the brand blends advanced medical innovation with hospitality-grade experiences to help people live healthier, longer lives. Through services like IV therapy, hormone optimization, peptide treatments, cryotherapy, and extensive functional medicine testing, Next Health empowers people to take control of their vitality from the inside out.
Yahoo
25-03-2025
- Business
- Yahoo
Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage. To view an enhanced version of this graphic, please visit: Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States. "We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach." Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity. While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders. For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit or contact ceo@ About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
